PL3023788T3 - Kompozycje neoantygenów specyficznych wobec nowotworu do zastosowania w leczeniu nowotworów - Google Patents

Kompozycje neoantygenów specyficznych wobec nowotworu do zastosowania w leczeniu nowotworów

Info

Publication number
PL3023788T3
PL3023788T3 PL15198284T PL15198284T PL3023788T3 PL 3023788 T3 PL3023788 T3 PL 3023788T3 PL 15198284 T PL15198284 T PL 15198284T PL 15198284 T PL15198284 T PL 15198284T PL 3023788 T3 PL3023788 T3 PL 3023788T3
Authority
PL
Poland
Prior art keywords
cancer
compositions
treatment
specific neoantigens
neoantigens
Prior art date
Application number
PL15198284T
Other languages
English (en)
Polish (pl)
Inventor
Nir Hacohen
Catherine Wu
Original Assignee
The General Hospital Corporation
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44915022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3023788(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The General Hospital Corporation, Dana-Farber Cancer Institute, Inc. filed Critical The General Hospital Corporation
Publication of PL3023788T3 publication Critical patent/PL3023788T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
PL15198284T 2010-05-14 2011-05-16 Kompozycje neoantygenów specyficznych wobec nowotworu do zastosowania w leczeniu nowotworów PL3023788T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33486610P 2010-05-14 2010-05-14
PCT/US2011/036665 WO2011143656A2 (en) 2010-05-14 2011-05-16 Compositions and methods of identifying tumor specific neoantigens
EP15198284.0A EP3023788B1 (en) 2010-05-14 2011-05-16 Compositions of tumor specific neoantigens for use in treating tumours
EP11781409.5A EP2569633B1 (en) 2010-05-14 2011-05-16 Compositions and methods of identifying tumor specific neoantigens

Publications (1)

Publication Number Publication Date
PL3023788T3 true PL3023788T3 (pl) 2020-07-27

Family

ID=44915022

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15198284T PL3023788T3 (pl) 2010-05-14 2011-05-16 Kompozycje neoantygenów specyficznych wobec nowotworu do zastosowania w leczeniu nowotworów

Country Status (14)

Country Link
US (8) US9115402B2 (2)
EP (4) EP2569633B1 (2)
JP (5) JP5948319B2 (2)
KR (4) KR102017898B1 (2)
CN (2) CN105648056A (2)
AU (1) AU2011252795B2 (2)
BR (2) BR112012029066A2 (2)
CA (2) CA2797868C (2)
DK (1) DK3023788T3 (2)
ES (3) ES3038392T3 (2)
HU (1) HUE049886T2 (2)
PL (1) PL3023788T3 (2)
PT (1) PT3023788T (2)
WO (1) WO2011143656A2 (2)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
CN102625832A (zh) 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
EP2569633B1 (en) * 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
PL3892295T3 (pl) * 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
EP3892295B1 (en) * 2011-05-24 2023-04-26 BioNTech SE Individualized vaccines for cancer
US20140303020A1 (en) * 2011-08-02 2014-10-09 The University Of Tokyo Method for Assessing Myelodysplastic Syndrome or Myeloid Tumor Predisposition, Polypeptide and Antibody Therefor, and Candidate Screening Method for Therapeutic Drug or Prophylactic Drug Therefor
ES2602072T3 (es) * 2011-09-29 2017-02-17 Trovagene, Inc. Mutaciones en SF3B1 y leucemia linfocítica crónica
WO2013086464A1 (en) * 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
ES2748652T3 (es) 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CA2886218A1 (en) 2012-05-25 2013-11-28 Phosimmune, Inc. Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
WO2014012051A1 (en) * 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
US9561266B2 (en) 2012-08-31 2017-02-07 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
WO2014039675A2 (en) 2012-09-05 2014-03-13 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
LT2901341T (lt) 2012-09-28 2019-09-25 The University Of Connecticut Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui
EP3417874B1 (en) 2012-11-28 2024-09-11 BioNTech SE Individualized vaccines for cancer
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
EP3292873B1 (en) 2013-02-22 2019-05-01 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
KR102164405B1 (ko) 2013-03-14 2020-10-12 더 존스 홉킨스 유니버시티 나노스케일 인공 항원 제시 세포
EP2983702A2 (en) * 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US20160310584A1 (en) * 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines
KR20230076867A (ko) * 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
EP3090066A4 (en) * 2014-01-02 2017-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
CA2935878C (en) 2014-03-12 2023-05-02 Curevac Ag Combination of vaccination and ox40 agonists
EP3137100B1 (en) 2014-04-15 2023-12-20 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
CN113791220A (zh) * 2014-09-10 2021-12-14 豪夫迈·罗氏有限公司 免疫原性突变体肽筛选平台
EP3191121B1 (en) * 2014-09-10 2020-05-27 The University of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
WO2016040900A1 (en) * 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
CA3017170C (en) 2014-09-17 2021-03-23 The Johns Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
SI3193917T1 (sl) * 2014-09-17 2022-02-28 Io Biotech Aps Sestavki cepiva, ki vsebujejo triptofan 2,3-dioksigenazo ali njene delce
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
JP6599450B2 (ja) 2014-10-02 2019-10-30 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
JP6991857B2 (ja) * 2014-10-10 2022-01-13 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
MA40737A (fr) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
JP2018516847A (ja) 2015-03-25 2018-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 生体高分子薬を送達するための組成物及び方法
US20190099475A1 (en) * 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
BR112017022845A2 (pt) 2015-04-23 2018-07-17 Nantomics, Llc neoepítopos de câncer
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
CN117467603A (zh) * 2015-04-27 2024-01-30 癌症研究技术有限公司 治疗癌症的方法
WO2016179006A1 (en) 2015-05-01 2016-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
EA201792501A1 (ru) 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
IL294183B2 (en) * 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
TW202241500A (zh) * 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
EP3350600A4 (en) * 2015-09-18 2019-04-17 Baylor College of Medicine DISTINCTION OF AN IMMUNOGENIC ANTIGEN OF A PATHOGEN AND CORRELATION WITH CLINICAL EFFECTIVENESS
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
EP3362929B1 (en) 2015-10-12 2020-08-12 Nantomics, LLC Viral neoepitopes and uses thereof
MX2018004544A (es) * 2015-10-12 2018-11-09 Nantomics Llc Composiciones y métodos para los neoepítopos de cáncer viral.
CN108700592B (zh) * 2015-10-12 2021-08-24 南托米克斯有限责任公司 新表位的迭代发现及其适应性免疫疗法和方法
CA3003251A1 (en) * 2015-10-12 2017-04-20 Nantomics, Llc Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
AU2016341309A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
EP3371594A1 (en) 2015-11-06 2018-09-12 Ventana Medical Systems, Inc. Representative diagnostics
TWI733719B (zh) * 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
ES2970865T3 (es) * 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
US11135221B2 (en) * 2015-12-23 2021-10-05 Moonshot Pharma Llc Methods for inducing an immune response
IL260030B2 (en) 2016-01-08 2025-12-01 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
WO2017139694A1 (en) * 2016-02-12 2017-08-17 Nantomics, Llc High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
CN105720176A (zh) * 2016-02-19 2016-06-29 京东方科技集团股份有限公司 一种胶囊量子点和发光二极管、制备方法及显示装置
WO2017143092A1 (en) 2016-02-19 2017-08-24 Nant Holdings Ip, Llc Methods of immunogenic modulation
KR20180117227A (ko) * 2016-03-24 2018-10-26 난트셀, 인크. 네오에피토프 제시를 위한 시퀀스들 및 시퀀스 배열들
CA3056212A1 (en) * 2016-04-07 2017-10-12 Bostongene Corporation Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
US20190062272A1 (en) * 2016-04-13 2019-02-28 Capten Therapeutics Inc. Small molecules for immunogenic treatment of cancer
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
US20190247435A1 (en) * 2016-06-29 2019-08-15 The Johns Hopkins University Neoantigens as targets for immunotherapy
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
SG11201900132QA (en) * 2016-07-20 2019-02-27 Biontech Rna Pharmaceuticals Gmbh Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
AU2017305396A1 (en) * 2016-08-02 2019-02-21 Nant Holdings Ip, Llc Transfection of dendritic cells and methods therefor
US20190237158A1 (en) * 2016-08-31 2019-08-01 Medgenome, Inc. Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
US10350280B2 (en) 2016-08-31 2019-07-16 Medgenome Inc. Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
MX2019002925A (es) 2016-09-15 2019-09-05 Idera Pharmaceuticals Inc Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
WO2018057447A1 (en) * 2016-09-23 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
WO2018071796A2 (en) * 2016-10-13 2018-04-19 The Johns Hopkins University Compositions and methods for identifying functional anti-tumor t cell responses
CN110520530A (zh) * 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
WO2018089637A1 (en) 2016-11-11 2018-05-17 Nantbio, Inc. Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
WO2018102613A2 (en) 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
BR112019015797A2 (pt) * 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
US20190351040A1 (en) * 2017-02-01 2019-11-21 Modernatx, Inc. Rna cancer vaccines
US10859566B2 (en) 2017-03-20 2020-12-08 Genocea Biosciences, Inc. Treatment methods
WO2018183544A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Method for identification of retained intron tumor neoantigens from patient transcriptome
CA3058807A1 (en) 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
CA3060569A1 (en) * 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
US11779637B2 (en) 2017-04-24 2023-10-10 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
US20200199660A1 (en) 2017-05-10 2020-06-25 The Broad Institute, Inc. Methods and compositions for determination of mutations in single replication events
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
JP2020522479A (ja) * 2017-06-02 2020-07-30 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 個別化された癌ワクチンを作製する方法
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2018234506A2 (en) * 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
TWI832820B (zh) 2017-07-21 2024-02-21 美商伯克利之光生命科技公司 抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
WO2019023269A1 (en) 2017-07-25 2019-01-31 California Institute Of Technology DISCOVERING TROGOCYTOSE MEDIATION EPITOPES
WO2019036043A2 (en) * 2017-08-16 2019-02-21 Medgenome Inc. METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
CA3076918A1 (en) * 2017-10-02 2019-04-11 Curematch, Inc. Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
RU2020115161A (ru) * 2017-10-06 2021-11-08 Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи Днк моноклональных антител против ctla-4 для лечения и профилактики рака
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
EP3707245A1 (en) * 2017-11-06 2020-09-16 Ludwig Institute for Cancer Research Ltd Method for expansion of lymphocytes
WO2019094396A1 (en) * 2017-11-07 2019-05-16 Nektar Therapeutics Immunotherapeutic combination for treating cancer
SG11202004116QA (en) 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
CN109682978B (zh) * 2017-11-30 2020-07-03 四川康德赛医疗科技有限公司 一种肿瘤突变肽mhc亲和力预测方法及其应用
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
EP3743102A1 (en) 2018-01-26 2020-12-02 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
WO2019147921A1 (en) 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
CN108491689B (zh) * 2018-02-01 2019-07-09 杭州纽安津生物科技有限公司 基于转录组的肿瘤新抗原鉴定方法
EP3759131A4 (en) * 2018-02-27 2021-12-01 Gritstone bio, Inc. NEOANTIGEN IDENTIFICATION WITH PAN ALLELE MODELS
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
AU2019275072A1 (en) 2018-05-23 2021-01-21 Seattle Project Corp. Shared antigens
WO2019227106A1 (en) 2018-05-25 2019-11-28 The Wistar Institute Tumor-specific neoantigens and methods of using the same
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
IL280113B2 (en) 2018-07-26 2025-11-01 Curevac Netherlands B V Cancer vaccines for uterine cancer
WO2020022900A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
WO2020022903A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
US20220349010A1 (en) 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
CA3106564A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
IL321692A (en) 2018-07-26 2025-08-01 Curevac Netherlands B V Cancer vaccines for colorectal cancer
CN109021062B (zh) * 2018-08-06 2021-08-20 倍而达药业（苏州）有限公司 一种肿瘤新抗原的筛选方法
CN121354685A (zh) 2018-08-31 2026-01-16 夸登特健康公司 无细胞dna中的微卫星不稳定性检测
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
TW202028224A (zh) 2018-09-17 2020-08-01 德商英麥提克生物技術股份有限公司 B*44限制肽在抗癌免疫治療的用途和相關方法
US11993766B2 (en) 2018-09-21 2024-05-28 Bruker Cellular Analysis, Inc. Functionalized well plate, methods of preparation and use thereof
MX2021003654A (es) 2018-09-27 2021-05-28 Nykode Therapeutics AS Metodo para seleccionar neoepitopes.
KR20210078526A (ko) 2018-10-18 2021-06-28 버클리 라잇츠, 인크. 원 항원 제시 합성 표면, 활성화된 t 세포, 및 이들의 용도
SG11202104611YA (en) 2018-11-08 2021-06-29 Neximmune Inc T cell compositions with improved phenotypic properties
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
CN109706065A (zh) * 2018-12-29 2019-05-03 深圳裕策生物科技有限公司 肿瘤新生抗原负荷检测装置及存储介质
MX2021010089A (es) 2019-02-20 2021-12-10 Rubius Therapeutics Inc Células eritroides diseñadas que incluyen polipéptidos que presentan antígeno cargable y métodos de uso.
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
US12427195B1 (en) * 2019-03-11 2025-09-30 La Jolla Institute For Immunology Methods of neoantigen identification
WO2020185010A1 (ko) * 2019-03-12 2020-09-17 (주)신테카바이오 인공지능모델기반 분자동역학 빅데이터를 활용한 신생항원 면역치료정보 제공 시스템 및 방법
EP3963335B1 (en) * 2019-05-03 2024-08-21 Epivax Therapeutics, Inc. Neoantigens in cancer
WO2020227255A1 (en) * 2019-05-06 2020-11-12 The Regents Of The University Of Michigan Targeted therapy
CN112011833B (zh) * 2019-05-30 2024-04-26 上海桀蒙生物技术有限公司 筛选和分离肿瘤新生抗原的方法
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
CN110322925B (zh) * 2019-07-18 2021-09-03 杭州纽安津生物科技有限公司 一种预测融合基因产生新生抗原的方法
CN110706747B (zh) * 2019-09-17 2021-09-07 北京橡鑫生物科技有限公司 检测肿瘤新生抗原多肽的方法和装置
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes
US20230212243A1 (en) * 2020-05-12 2023-07-06 Institut Curie Neoantigenic Epitopes Associated with SF3B1 Mutations
JP7153287B2 (ja) * 2020-05-12 2022-10-14 住友ファーマ株式会社 癌を処置するための医薬組成物
WO2021252904A1 (en) 2020-06-11 2021-12-16 Massachusetts Institute Of Technology Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
MX2023001815A (es) 2020-08-13 2023-04-11 Biontech Us Inc Metodos y composiciones de fabricacion de celulas t.
GB2613718A (en) * 2020-08-31 2023-06-14 World Biotech Regenerative Medical Group Ltd Personalized immunogenic compositions and methods for producing and using same
KR102552632B1 (ko) * 2020-11-06 2023-07-06 사회복지법인 삼성생명공익재단 중추신경계 림프종을 진단하기 위한 마커, 이를 포함하는 중추신경계 림프종 진단 키트 및 중추신경계 림프종을 진단하는 방법
AU2022245391A1 (en) * 2021-03-26 2023-10-12 The Translational Genomics Research Institute Methods and compounds for neoantigen vaccines
JP2024517793A (ja) 2021-04-30 2024-04-23 ティゲン・ファーマ・ソシエテ・アノニム 単一容器リンパ球拡大
US20230173046A1 (en) * 2021-05-27 2023-06-08 Amazon Technologies, Inc. Multicomponent chemical composition of a peptide-based neoantigen vaccine
WO2023025404A1 (en) 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
CN115772564B (zh) * 2021-09-08 2023-08-18 广州市基准医疗有限责任公司 用于辅助检测肺癌体细胞atm基因融合突变的甲基化生物标记物及其应用
EP4419716A1 (en) 2021-10-21 2024-08-28 CureVac Netherlands B.V. Cancer neoantigens
CN116287158A (zh) * 2021-12-08 2023-06-23 初源海生物科技(深圳)有限公司 一种新抗原鉴定和疗效预测方法
CN119072330A (zh) 2022-03-14 2024-12-03 世代生物公司 异源初免加强疫苗组合物和使用方法
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2024097864A1 (en) 2022-11-02 2024-05-10 Tigen Pharma Sa Expansion of lymphocytes
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
EP4474016A1 (en) 2023-06-07 2024-12-11 Julius-Maximilians-Universität Würzburg Strategies to target extracellularly accessible ras protein
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US911A (en) 1838-09-12 Mode of fastening bedsteabs
US221332A (en) 1879-11-04 Improvement in fire-escapes
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US5589406A (en) 1993-07-30 1996-12-31 Ag Technology Co., Ltd. Method of making TFT display
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2344995A1 (en) * 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
CN100352921C (zh) * 1999-05-06 2007-12-05 威克福雷大学 用于鉴定引起免疫反应的抗原的组合物和方法
ATE512666T1 (de) * 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen
WO2001055177A2 (en) * 2000-01-28 2001-08-02 Statens Serum Institut Methods to identify ctl epitopes of hiv
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
EP2287186B1 (en) * 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
WO2003106692A2 (en) 2002-06-13 2003-12-24 Merck Patent Gmbh Methods for the identification of all-antigens and their use for cancer therapy and transplantation
PT1620456E (pt) * 2003-04-18 2014-04-15 Biotech Synergy Inc Péptidos antigénicos hla-a2 associados a tumor e suas composições
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US20070112754A1 (en) 2005-11-15 2007-05-17 Honeywell International Inc. Method and apparatus for identifying data of interest in a database
JP2009532664A (ja) * 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 癌の治療のためのノボペプチドの同定および使用
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
KR101323540B1 (ko) 2007-02-07 2013-10-29 사이단호진한다이비세이부쯔뵤우겐큐우카이 암의 치료제
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
PT2186889E (pt) * 2007-08-20 2015-06-17 Oncotherapy Science Inc Péptido cdca1 e agente farmacêutico que o compreende
EP2238265A4 (en) 2007-12-28 2012-01-18 Wayne John Cancer Inst USE OF THE METHYLATION STATE OF MINT-LOCI AND TUMOR ASSOCIATED GENES AS A MARKER FOR MELANOMA AND MAMMARIAN CARCINOMA
US20110097312A1 (en) * 2008-02-15 2011-04-28 Board Of Regents, The University Of Texas System Anti-cancer vaccines
CA2738031C (en) 2008-09-22 2022-11-29 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
US8369279B2 (en) 2010-03-10 2013-02-05 Broadcom Corporation Method and system for iterative multiple frequency hypothesis testing with cell-ID detection in an E-UTRA/LTE UE receiver
PE20121359A1 (es) 2009-12-10 2012-10-15 Merck Patent Gmbh Composicion farmaceutica que comprende oligopeptidos
WO2011073215A2 (en) 2009-12-14 2011-06-23 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
CA2801314A1 (en) 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
GB2487632B (en) 2011-01-14 2014-03-12 Genefirst Ltd Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
CN103906848B (zh) 2011-08-18 2016-03-02 雀巢产品技术援助有限公司 用于检测等位变体的组合物和方法
WO2013123031A2 (en) 2012-02-15 2013-08-22 Veridex, Llc Highly sensitive method for detecting low frequency mutations
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US10176294B2 (en) 2013-03-15 2019-01-08 The Broad Institute, Inc. Accurate typing of HLA through exome sequencing
EP3152569B1 (en) 2014-06-05 2020-06-10 AIMM Therapeutics B.V. Means and methods for determining t cell recognition
DK3198026T3 (da) 2014-08-07 2020-01-20 Pharmassist Ltd Fremgangsmåde til bestemmelse af pik3ca-mutationsstatus i en prøve
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
US20180127803A1 (en) 2015-05-10 2018-05-10 Quandx Inc. Ultra sensitive probes for detection of nucleic acid
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法

Also Published As

Publication number Publication date
WO2011143656A3 (en) 2012-08-23
CN103180730A (zh) 2013-06-26
CA3197245A1 (en) 2011-11-17
ES3038392T3 (en) 2025-10-13
CA2797868C (en) 2023-06-20
US20160331822A1 (en) 2016-11-17
US9115402B2 (en) 2015-08-25
BR112012029066A2 (pt) 2020-09-01
CA2797868A1 (en) 2011-11-17
JP2016156828A (ja) 2016-09-01
AU2011252795A1 (en) 2012-11-08
EP2569633A2 (en) 2013-03-20
HUE049886T2 (hu) 2020-10-28
EP2569633B1 (en) 2016-02-10
JP7008049B2 (ja) 2022-02-10
DK3023788T3 (da) 2020-04-27
JP7801134B2 (ja) 2026-01-16
US20160008447A1 (en) 2016-01-14
KR20180105743A (ko) 2018-09-28
PT3023788T (pt) 2020-05-18
US20110293637A1 (en) 2011-12-01
US20180055922A1 (en) 2018-03-01
JP2013530943A (ja) 2013-08-01
EP4623996A2 (en) 2025-10-01
JP2022044632A (ja) 2022-03-17
KR102095670B1 (ko) 2020-03-31
ES2564841T3 (es) 2016-03-29
KR102315754B1 (ko) 2021-10-22
JP5948319B2 (ja) 2016-07-06
CN103180730B (zh) 2016-03-02
KR102017898B1 (ko) 2019-09-04
US10426824B1 (en) 2019-10-01
KR20130119845A (ko) 2013-11-01
US20190060432A1 (en) 2019-02-28
BR122021014039B1 (pt) 2021-12-14
EP3699266B1 (en) 2025-07-02
US20200016251A1 (en) 2020-01-16
EP3023788B1 (en) 2020-02-12
KR20210129254A (ko) 2021-10-27
WO2011143656A2 (en) 2011-11-17
JP2024045573A (ja) 2024-04-02
CN105648056A (zh) 2016-06-08
US20200069783A1 (en) 2020-03-05
EP3023788A1 (en) 2016-05-25
EP4623996A3 (en) 2025-12-31
JP6943545B2 (ja) 2021-10-06
KR102447139B1 (ko) 2022-09-23
EP3699266A1 (en) 2020-08-26
AU2011252795B2 (en) 2015-09-03
EP2569633A4 (en) 2014-05-14
JP2019135494A (ja) 2019-08-15
KR20190133281A (ko) 2019-12-02
ES2788863T3 (es) 2020-10-23

Similar Documents

Publication Publication Date Title
PL3023788T3 (pl) Kompozycje neoantygenów specyficznych wobec nowotworu do zastosowania w leczeniu nowotworów
PL2598531T3 (pl) Sposoby i kompozycje do terapii nowotworu wątroby
IL239007B (en) Eribulin for use in the treatment of breast cancer
PL2632452T3 (pl) Związki i kompozycje stosowane w leczeniu nowotworów
SMT201600430B (it) Inibitori di chinasi e loro uso nel trattamento del cancro
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
EP2675469A4 (en) COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL223201A (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
IL238400A (en) Triazulophyrazines as brd4 inhibitors for use in cancer treatment
IL238107B (en) Compositions comprising masitinib for use in treatment of cancer in patient subpopulations identified using predictor factors
IL220386B (en) Compositions for the liquidation of tumors and uses thereof
IL238177A0 (en) Methods and preparations for the treatment of cancer
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
IL226246A0 (en) Methods of treating cancer
PL2605764T3 (pl) Kompozycje do leczenia nowotworu
PL2742356T3 (pl) Środki prognostyczne w leczeniu nowotworów
BR112013014811A2 (pt) composição de tratamento de pano
LT2872176T (lt) Karboranilporfirinai, skirti naudoti vėžio gydymui
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
SMT201200064B (it) Composizioni per uso nel trattamento di sindromi mielodisplastiche
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
FI20105855A0 (fi) Transdermaaliset koostumukset ihmiskäyttöön
GB201208770D0 (en) Compounds for use in the treatment of adenovirus infections